Загрузка...
Wee1 inhibitor MK1775 sensitizes KRAS mutated NSCLC cells to sorafenib
Non-Small-Cell Lung Cancer (NSCLC) is a poorly chemosensitive tumor and targeted therapies are only used for about 15% of patients where a specific driving and druggable lesion is observed (EGFR, ALK, ROS). KRAS is one of the most frequently mutated genes in NSCLC and patients harboring these mutati...
Сохранить в:
| Опубликовано в: : | Sci Rep |
|---|---|
| Главные авторы: | , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Nature Publishing Group UK
2018
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5772438/ https://ncbi.nlm.nih.gov/pubmed/29343688 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-017-18900-y |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|